News | April 07, 2025
Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis
Amaran Biotech boasts Taiwan’s first fully automated robotic aseptic filling line, offering high-quality and low-waste filling solutions for high-value pharmaceuticals
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
Subscribe To Our Newsletter & Stay Updated
